

An S De Vriese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6987384/publications.pdf>

Version: 2024-02-01

120
papers

8,536
citations

53794

45
h-index

45317

90
g-index

122
all docs

122
docs citations

122
times ranked

8729
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2072-2079.	0.7	28
2	Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registry. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1361-1372.	2.9	5
3	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	5.2	82
4	Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1103-1107.	0.8	8
5	Acute glomerulonephritis. <i>Lancet, The</i> , 2022, 399, 1646-1663.	13.7	24
6	Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 385-396.	6.1	101
7	PEXIVAS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 307-309.	4.5	6
8	A Target Antigen-Based Approach to the Classification of Membranous Nephropathy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 577-591.	3.0	45
9	Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1474-1483.	6.1	87
10	Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents. <i>Clinical Infectious Diseases</i> , 2021, 73, 2145-2147.	5.8	62
11	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2390-2391.	6.1	0
12	Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2446-2448.	2.9	5
13	Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3208-3220.	6.1	74
14	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1833-1839.	4.5	27
15	Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 23-33.	0.7	31
16	IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 440-441.	1.9	33
17	In Reply to "Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?". <i>American Journal of Kidney Diseases</i> , 2020, 76, 598-599.	1.9	0
18	Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 186-196.	6.1	116

#	ARTICLE	IF	CITATIONS
19	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	5.2	7
20	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. <i>Kidney International</i> , 2019, 95, 429-438.	5.2	123
21	Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 759-774.	6.1	186
22	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2018, 93, 991-1008.	3.0	82
23	Measurement of pulse wave velocity, augmentation index, and central pulse pressure in atrial fibrillation: a proof of concept study. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 627-632.	2.3	13
24	Other consequences from monoclonal immunoglobulins/fragments. , 2018, , .		0
25	Should Statins Be Banned from Dialysis?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1675-1676.	6.1	21
26	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i14-i21.	0.7	15
27	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i139-i145.	0.7	59
28	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. <i>Kidney International</i> , 2017, 91, 787-789.	5.2	161
29	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	3.1	15
30	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1772-1781.	3.0	39
31	A Proposal for a Serology-Based Approach to Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 421-430.	6.1	273
32	Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2017, 184, 37-46.	2.7	81
33	P143 VALIDITY OF PULSE WAVE VELOCITY AND AUGMENTATION INDEX MEASUREMENTS IN PATIENTS WITH ATRIAL FIBRILLATION. <i>Artery Research</i> , 2017, 20, 96.	0.6	0
34	Fibromuscular dysplasia - results of a multicentre study in Flanders. <i>Vasa - European Journal of Vascular Medicine</i> , 2017, 46, 211-218.	1.4	13
35	Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings. <i>Clinical Nephrology</i> , 2017, 88, 277-283.	0.7	7
36	Diagnosis of complement alternative pathway disorders. <i>Kidney International</i> , 2016, 89, 278-288.	5.2	74

#	ARTICLE	IF	CITATIONS
37	The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. CKJ: Clinical Kidney Journal, 2016, 9, 273-279.	2.9	77
38	The atrial fibrillation conundrum in dialysis patients. American Heart Journal, 2016, 174, 111-119.	2.7	26
39	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	6.1	210
40	C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?. Journal of Nephrology, 2016, 29, 203-209.	2.0	18
41	High homocysteine induces betaine depletion. Bioscience Reports, 2015, 35, .	2.4	20
42	Con: Biomarkers in glomerular diseases: putting the cart before the wheel?. Nephrology Dialysis Transplantation, 2015, 30, 885-890.	0.7	6
43	In Reply to "Hemodialysis Catheters: Which Design Is More Cost-effective?" and "Use of an Uncensored Primary Outcome in a Catheter Design Trial?". American Journal of Kidney Diseases, 2015, 66, 171.	1.9	0
44	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	6.1	84
45	Dose-Finding Study of Rivaroxaban in Hemodialysis Patients. American Journal of Kidney Diseases, 2015, 66, 91-98.	1.9	119
46	C4d as a Diagnostic Tool in Proliferative GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2852-2859.	6.1	106
47	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 898-899.	0.7	1
48	Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrology Dialysis Transplantation, 2014, 29, 1385-1390.	0.7	105
49	A Bone Scan, No Mistake!. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4447-4448.	3.6	0
50	Hemodialysis Catheter Design and Catheter Performance: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2014, 64, 902-908.	1.9	48
51	Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1708-1714.	3.8	33
52	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. Journal of the American Society of Nephrology: JASN, 2013, 24, 1981-1994.	6.1	96
53	Should we screen for coronary artery disease in asymptomatic chronic dialysis patients?. Kidney International, 2012, 81, 143-151.	5.2	36
54	Reversion of cerebral artery stenoses due to tuberculomas with TNF- α antibodies. Clinical Neurology and Neurosurgery, 2012, 114, 1016-1018.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Vancomycin Dosing in Patients on Intermittent Hemodialysis. <i>Seminars in Dialysis</i> , 2011, 24, 50-55.	1.3	39
56	Diffuse Alveolar Hemorrhage Induced by Everolimus. <i>Chest</i> , 2010, 137, 456-459.	0.8	36
57	Recent changes in vancomycin use in renal failure. <i>Kidney International</i> , 2010, 77, 760-764.	5.2	84
58	Indications to Start Kidney Replacement Therapy. , 2010, , 471-479.		0
59	Staphylococcus aureus Infections in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1388-1400.	4.5	100
60	Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in hemodialysis patients. <i>Kidney International</i> , 2009, 76, 428-436.	5.2	10
61	Oral Vitamin C Administration Increases Lipid Peroxidation in Hemodialysis Patients. <i>Nephron Clinical Practice</i> , 2008, 108, c28-c34.	2.3	18
62	Renal side effects of anti-VEGF therapy in man: a new test system. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2778-2780.	0.7	19
63	Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1330-1335.	0.7	26
64	Prevention of contrast-induced nephropathy: a critical review. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 336-347.	2.0	43
65	Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study. <i>Journal of Hepatology</i> , 2007, 46, 804-815.	3.7	5
66	Steroid-resistant sarcoidosis: is antagonism of TNF- α the answer?. <i>Clinical Science</i> , 2007, 112, 281-289.	4.3	44
67	Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. <i>Clinical Infectious Diseases</i> , 2006, 42, 1111-1117.	5.8	270
68	Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. <i>Liver International</i> , 2006, 26, 889-898.	3.9	65
69	Effects of Peritoneal Dialysis on the Vascular Bed of Peritoneal Membrane. , 2006, 150, 84-89.		3
70	A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 324-329.	0.7	65
71	Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3364-3367.	0.7	44
72	Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2549-2555.	0.7	122

#	ARTICLE	IF	CITATIONS
73	Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. <i>Kidney International</i> , 2005, 67, 1559-1565.	5.2	99
74	The John F. Maher Recipient Lecture 2004: Rage in the Peritoneum. <i>Peritoneal Dialysis International</i> , 2005, 25, 8-11.	2.3	18
75	Animal Models in Peritoneal Dialysis Research: A Need for Consensus. <i>Peritoneal Dialysis International</i> , 2005, 25, 16-24.	2.3	28
76	Effects of New Peritoneal Dialysis Solutions on Leukocyte Recruitment in the Rat Peritoneal Membrane. <i>Nephron Experimental Nephrology</i> , 2005, 101, e139-e145.	2.2	24
77	Pathophysiological Role of Vascular Endothelial Growth Factor in the Remnant Kidney. <i>Nephron Experimental Nephrology</i> , 2005, 101, e9-e15.	2.2	31
78	Immunopathological changes in a uraemic rat model for peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1350-1361.	0.7	38
79	Analytical and biochemical aspects associated with supraphysiological creatine intake. <i>Clinica Chimica Acta</i> , 2005, 351, 217-219.	1.1	4
80	Cytochrome P450-2C11 mRNA Is Not Expressed in Endothelial Cells Dissected from Rat Renal Arterioles. <i>Nephron Physiology</i> , 2005, 99, p43-p49.	1.2	2
81	The Effects of Peritoneal Dialysis Solutions on Peritoneal Host Defense. <i>Peritoneal Dialysis International</i> , 2004, 24, 123-138.	2.3	55
82	Endothelium-Derived Hyperpolarizing Factor Mediated Renal Vasodilatory Response Is Impaired During Acute and Chronic Hyperhomocysteinemia. <i>Circulation</i> , 2004, 109, 2331-2336.	1.6	62
83	Prohepcidin accumulates in renal insufficiency. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 387-9.	2.3	80
84	Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1092-1097.	0.7	29
85	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. <i>Liver International</i> , 2004, 24, 63-68.	3.9	35
86	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. <i>Kidney International</i> , 2004, 65, 2003-2017.	5.2	411
87	Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. <i>Kidney International</i> , 2004, 66, 1257-1265.	5.2	171
88	Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. <i>Kidney International</i> , 2004, 66, 2422-2428.	5.2	26
89	From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines. <i>Endocrine Reviews</i> , 2004, 25, 971-1010.	20.1	309
90	Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 139-145.	1.6	28

#	ARTICLE	IF	CITATIONS
91	Renal angiomyolipoma in association with pulmonary lymphangiomyomatosis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 877-883.	1.9	24
92	Creatine supplementation decreases homocysteine in an animal model of uremia. <i>Kidney International</i> , 2003, 64, 1331-1337.	5.2	39
93	Sildenafil in rats with cirrhosis and portal hypertension: Systemic and splanchnic haemodynamic effects. <i>Gastroenterology</i> , 2003, 124, A736.	1.3	0
94	Prevention and Treatment of Acute Renal Failure in Sepsis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 792-805.	6.1	115
95	Effects of Conventional and New Peritoneal Dialysis Fluids on Leukocyte Recruitment in the Rat Peritoneal Membrane. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1296-1306.	6.1	86
96	Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2596-2600.	0.7	33
97	The emerging role of VEGF in diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1427-1430.	0.7	36
98	Pharmacologic treatment of acute renal failure in sepsis. <i>Current Opinion in Critical Care</i> , 2003, 9, 474-480.	3.2	27
99	Prevention and nondialytic treatment of acute renal failure. <i>Current Opinion in Critical Care</i> , 2003, 9, 481-490.	3.2	58
100	Recent Concepts in the Molecular Biology of the Peritoneal Membrane – Implications for More Biocompatible Dialysis Solutions. <i>Blood Purification</i> , 2003, 21, 14-23.	1.8	39
101	Peritoneal Microcirculation. , 2003, 140, 56-69.		4
102	Factors influencing the progression of diabetic nephropathy. , 2003, , 75-96.		0
103	Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody. <i>Diabetes</i> , 2002, 51, 3090-3094.	0.6	288
104	The Effects of Heparin Administration in an Animal Model of Chronic Peritoneal Dialysate Exposure. <i>Peritoneal Dialysis International</i> , 2002, 22, 566-572.	2.3	29
105	Increased Leukocyte Rolling in Newly Formed Mesenteric Vessels in the Rat during Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2002, 22, 655-662.	2.3	18
106	Interesting News in Peritoneal Dialysis. <i>Nephron</i> , 2002, 92, 763-771.	1.8	0
107	Effects of connexin-mimetic peptides on nitric oxide synthase- and cyclooxygenase-independent renal vasodilation. <i>Kidney International</i> , 2002, 61, 177-185.	5.2	70
108	Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?. <i>Kidney International</i> , 2002, 61, 1199-1209.	5.2	39

#	ARTICLE	IF	CITATIONS
109	Experimental diabetes induces functional and structural changes in the peritoneum. <i>Kidney International</i> , 2002, 62, 668-678.	5.2	31
110	What Happens to the Peritoneal Membrane in Long-Term Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2001, 21, 9-18.	2.3	46
111	Non Anticoagulant Effects of Heparin: Implications for Animal Models of Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2001, 21, 354-356.	2.3	12
112	Intravital microscopy: an integrated evaluation of peritoneal function and structure. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 657-660.	0.7	17
113	Neovascularization in the peritoneal membrane: does it play a role in ultrafiltration failure?. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2143-2145.	0.7	17
114	Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: Role of nitric oxide. <i>Kidney International</i> , 2001, 60, 202-210.	5.2	55
115	Glucotoxicity of the peritoneal membrane: the case for VEGF. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2299-2302.	0.7	15
116	Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 993-1000.	6.1	394
117	Vascular Endothelial Growth Factor Is Essential for Hyperglycemia-Induced Structural and Functional Alterations of the Peritoneal Membrane. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1734-1741.	6.1	147
118	Endothelial dysfunction in diabetes. <i>British Journal of Pharmacology</i> , 2000, 130, 963-974.	5.4	966
119	Off-Line Analysis of Red Blood Cell Velocity in Renal Arterioles. <i>Journal of Vascular Research</i> , 2000, 37, 26-31.	1.4	45
120	Influence of vasoactive intestinal polypeptide and NGnitro-L-arginine methyl ester on cholinergic neurotransmission in the rat gastric fundus. <i>European Journal of Pharmacology</i> , 1992, 221, 235-242.	3.5	44